Michael J. Allegrezza

Author

The Wistar Institute

Also Known As

M J Allegrezza, Michael Allegrezza, Michael J Allegrezza, Michael J. Allegrezza, Michael J. Allegrezza

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

The Wistar Institute University of Pennsylvania Christiana Care Health System Consejo Nacional de Investigaciones Científicas y Técnicas Dartmouth College

About

Michael J. Allegrezza is an author at The Wistar Institute specializing in medicine, cell biology, and tumor immunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.1K
2	Cell Biology	6	6	1.1K
3	Immunology	5	5	965
4	Cell Signaling	4	4	672
5	Pathology	2	2	328

Michael J. Allegrezza

Publications

Citations

H-Index

Page 1

	Year	Citations
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression Hengrui Zhu, Fee Bengsch, Nikolaos Svoronos, Cell Reports Cancer ImmunosurveillancePd-l1 ExpressionPd-l1 SignalingBet InhibitorImmunology	2016	417
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations Curtis H. Kugel, Stephen M. Douglass, Marie R. Webster, Clinical Cancer Research	2018	347
Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation Melanie R. Rutkowski, Tom L. Stephen, Nikolaos Svoronos, Cancer Cell InflammationCancer ImmunosurveillanceMedicineInnate Immune SystemImmunology	2014	301
Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells Nikolaos Svoronos, Alfredo Perales‐Puchalt, Michael J. Allegrezza, Cancer Discovery	2016	215
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells Tom L. Stephen, Kyle K. Payne, Ricardo A. Chaurio, Immunity Tumor-reactive T CellsCancer ImmunosurveillanceEpigenetic RegulationCell SignalingMedicine	2017	151
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target Alfredo Perales‐Puchalt, Nikolaos Svoronos, Melanie R. Rutkowski, Clinical Cancer Research	2016	116
Transforming Growth Factor β-Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression Tom L. Stephen, Melanie R. Rutkowski, Michael J. Allegrezza, Immunity Cancer ImmunosurveillanceImmunologyTumor ImmunityImmune RegulationT Cell Immunity	2014	114
Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells Amelia J. Tesone, Melanie R. Rutkowski, Eva Brencicova, Cell Reports ImmunologyImmunologic MechanismCancer BiologyTumor BiologyInflammation	2016	106
Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy Alfredo Perales‐Puchalt, Jairo Pérez‐Sanz, Kyle K. Payne, Journal of Leukocyte Biology	2018	87
Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis Michael J. Allegrezza, Melanie R. Rutkowski, Tom L. Stephen, Cancer Research	2016	60

Page 1